LUMIRADX LTD (LMDX) Stock Price, Forecast & Analysis
USA - NASDAQ:LMDX - KYG5709L1095 - Common Stock
LMDX Key Statistics, Chart & Performance
The current stock price of LMDX is 0.016 USD. In the past month the price decreased by -84.1%. In the past year, price decreased by -98.21%.
LMDX Latest News, Press Relases and Analysis
LMDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.05 | 226.26B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.5 | 196.01B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.63 | 147.02B | ||
| SYK | STRYKER CORP | 27.3 | 137.45B | ||
| BDX | BECTON DICKINSON AND CO | 13.34 | 55.13B | ||
| IDXX | IDEXX LABORATORIES INC | 53.15 | 53.62B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.7 | 49.34B | ||
| RMD | RESMED INC | 24.87 | 35.93B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.47 | 32.42B | ||
| PODD | INSULET CORP | 72.97 | 23.47B | ||
| DXCM | DEXCOM INC | 32.35 | 23.60B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.01 | 17.65B |
Related stock screener links
About LMDX
Company Profile
LumiraDX Ltd. is a next-generation point of care diagnostics company, which engages in the provision of an innovative diagnostic platform that supports a menu of tests with lab-comparable performance at the point of care. The firm is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The firm has developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless, secure digital connectivity. The firm offers a menu of lab comparable tests on a single portable platform, with more than 30 assays on the market and in various stages of development, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The company also supports laboratory testing in an accessible high-throughput format to leverage molecular laboratory operations. Its diagnostic testing solutions are being deployed globally by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and others.
Company Info
LUMIRADX LTD
PO Box 1350, Windward 3, Regatta Office
George Town KY
CEO: Larry J. Neiterman
Employees: 1210
Phone: 13546400540
LUMIRADX LTD / LMDX FAQ
Can you describe the business of LUMIRADX LTD?
LumiraDX Ltd. is a next-generation point of care diagnostics company, which engages in the provision of an innovative diagnostic platform that supports a menu of tests with lab-comparable performance at the point of care. The firm is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The firm has developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless, secure digital connectivity. The firm offers a menu of lab comparable tests on a single portable platform, with more than 30 assays on the market and in various stages of development, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The company also supports laboratory testing in an accessible high-throughput format to leverage molecular laboratory operations. Its diagnostic testing solutions are being deployed globally by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and others.
What is the current price of LMDX stock?
The current stock price of LMDX is 0.016 USD. The price decreased by -53.49% in the last trading session.
Does LUMIRADX LTD pay dividends?
LMDX does not pay a dividend.
How is the ChartMill rating for LUMIRADX LTD?
LMDX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting LMDX stock to perform?
8 analysts have analysed LMDX and the average price target is 1.22 USD. This implies a price increase of 7550% is expected in the next year compared to the current price of 0.016.
Can you provide the upcoming earnings date for LUMIRADX LTD?
LUMIRADX LTD (LMDX) will report earnings on 2024-03-19, after the market close.
LMDX Technical Analysis
LMDX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to LMDX. LMDX may be in some trouble as it scores bad on both profitability and health.
LMDX Financial Highlights
Over the last trailing twelve months LMDX reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS increased by 1.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.18% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LMDX Forecast & Estimates
8 analysts have analysed LMDX and the average price target is 1.22 USD. This implies a price increase of 7550% is expected in the next year compared to the current price of 0.016.
For the next year, analysts expect an EPS growth of 70.33% and a revenue growth -64.72% for LMDX